At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Acetyl-L-Carnitinedrug
Likely dose
Acetyl-L-Carnitine 4 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock
In Brief
A Phase 2 clinical trial evaluating Acetyl-L-Carnitine for Septic Shock. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeptic Shock
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedJan 2008
Primary CompletionAug 2009
Study CompletionSep 2009
TodayJul 2026
First PostedJan 14, 2008
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.5 years ago
Interventions
Acetyl-L-Carnitinedrug
Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours